40 results
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
14 May 24
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
8:03am
innovative programs are progressing through clinical trials and moving closer to addressing the significant unmet needs of individuals with developmental
8-K
EX-99.1
92y 92vsfh
13 May 21
Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:44pm
8-K
EX-99.1
kn6u g9k37jhti5lsc
3 Mar 21
Regulation FD Disclosure
10:05am
424B5
3invl51 ku19gs15ia
20 Nov 20
Prospectus supplement for primary offering
4:23pm
424B5
u1s788hr0z3
26 Aug 20
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
g43dj
25 Aug 20
Other Events
7:00am
8-K
EX-99.1
h0f6ev 7o
19 Jun 20
Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome
8:06am
424B5
q1c7ujpnjc1dustw
12 Nov 19
Prospectus supplement for primary offering
8:02am